Version history

{
  "session_id": "sess_SDA-BIOMNI-BIOMARKE-34ec007c",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "mini-max",
  "action": "critique",
  "content": "\n\n# Critical Evaluation: Multi-modal AD Biomarker Hypotheses\n\n---\n\n## Hypothesis 1: Synergistic Information Gain from Orthogonal Modalities\n\n### Weaknesses\n\n**1. \"Orthogonal\" claim is overstated.**\nThe AT(N) framework explicitly models a *cascade*, not independent streams. Aβ triggers tau which causes neurodegeneration—these are mechanistically linked, not independent. \"Orthogonal\" implies near-zero shared variance; empirically, plasma p-tau217 and amyloid PET share significant variance (Spearman ρ ≈ 0.6–0.7 in bioFINDER). True orthogonality requires demonstration, not assumption.\n\n**2. Ceiling effects argument lacks grounding.**\nThe assertion that single markers suffer ceiling effects is not well-supported. P-tau217 reaches AUC >0.93 for amyloid PET positivity (Palmqvist et al., 2023) and AUC ~0.95 for clinical diagnosis. Where is the ceiling being hit? If single markers already achieve high discriminatory accuracy, adding modalities yields diminishing returns.\n\n**3. Poorly specified interaction target.**\nAPOE genotype × biomarker interaction modifies risk—but *how*? In what direction? At what disease stage? This is not operationalized. Without specifying the expected interaction structure, the hypothesis cannot be falsified.\n\n**4. Missing comparator problem.**\n\"Outperforms single modalities\" requires a defined benchmark. What single modality? Which preprocessing pipeline? Which cohort? Comparative advantage is not demonstrated; it's asserted.\n\n### Counter-evidence\n\n- Meta-analyses (Swanson et al., 2021; Rindell et al., 2023) show p-tau217 alone matches or exceeds many multimodal composite scores in head-to-head comparisons.\n- The EMIF-AD study (Lopes et al., 2022) found incremental AUC gain from adding MRI to plasma p-tau was marginal (~0.02) in community-based cohorts.\n- Biomarker panel studies in population-screened (vs. clinic-referred) cohorts consistently show smaller added value from imaging/P RS.\n\n### Falsification Criteria\n\n- If a single plasma marker (p-tau217) achieves AUC ≥ panel AUC minus experimental margin of error (e.g., <0.03), the \"orthogonal complementarity\" claim is weakened.\n- If variance decomposition shows >70% of panel predictive power attributable to a single modality in independent validation, the synergy claim fails.\n- If the APOE × biomarker interaction explains <5% incremental variance after accounting for main effects, the stated target mechanism is insufficient.\n\n### Revised Confidence: **0.62**\nThe AT(N) framework is solid, but the *incremental* value of multimodal combination over best-in-class single markers is not established for clinical use cases. Confidence in the specific *synergy* claim is lower than asserted.\n\n---\n\n## Hypothesis 2: Machine Learning Integration Detects Non-linear Biomarker Interactions\n\n### Weaknesses\n\n**1",
  "tokens_used": "703"
}